1. Scrip

2021 Marked New Era Of Domestic Collaboration in China

But M&A Outlook Still Muted?

 
• By Dexter Jie Yan

Major deals showed an increasing focus on domestic tie-ups while an unsatiable appetite for innovation drove drug firms to actively seek out biotechs for collaboration.

2021 or 2022 first year of collaborations
past year unveiled a new era of collaborations between biotechs and biopharmas in China • Source: Alamy

2021 marked a new era of collaboration in China between domestic biotechs and the country's large drug makers, many of which have been relying on generics and traditional medicines. This increasing inward-looking trend could set the stage for acquisitions by larger firms with deep pockets, industry insiders predict.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia